Smithkline Beecham Corporation

Glaxo Group Limited

Beecham Group Plc

Ian Thomson Forbes

David G Cooper

Vincenzo Garzya

Paul Adrian Wyman

Graham Elgin Jones

David Thomas Davies

Graham Walker

Jian Jin

Brian W Budzik

Dongchuan Shi

Dale James Johnson

Mervyn Thompson

Laramie Mary Gaster

Keith Raymond Mulholland

David Malcolm Duckworth

Paul William Smith

Graeme Irvine Stevenson

Francis D King

Andrew Lightfoot

Roger T Martin

Shirley Katherine Rahman

Peter Ham

Andrew Derrick Gribble

Andrew H Payne

Christopher Norbert Johnson

Steven Mark Bromidge

Angela Moghe

David Gwyn Cooper

Yann Louchart

Compounds of formula (I) and salts and solvates are provided: wherein Ris fluoro, Ris selected from hydrogen, halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, and Calkoxy substituted with one or more fluorine atoms; and Ris selected from halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy and Calkoxy substituted with one or more fluorine atoms, and Q is hydrogen or Calkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Compounds which have activity at M1 receptor and their uses in medicine

Compounds of formula (I) or a salt thereof are provided: wherein R, R, R, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

[object Object]

Compounds of formula (I) and salts thereof are provided: wherein R, R, R, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Compounds of formula (I) and salts are provided: wherein Ris selected from hydrogen, halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or Calkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Benzimidazolones which have activity at M1 receptor

Compounds of formula (I) and salts are provided: wherein Ris selected from halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano; Ris selected from halogen, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy, Calkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or Calkyl. The compounds are Magonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Compounds of formula (I) and salts are provided: wherein Ris fluoro, Ris selected from hydrogen, halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Calkoxy, and Calkoxy substituted with one or more fluorine atoms; and Ris selected from halogen, cyano, Calkyl, Calkyl substituted with one or more fluorine atoms, Ccycloalkyl, Ccycloalkyl substituted with one or more fluorine atoms, Calkoxy and Calkoxy substituted with one or more fluorine atoms, and Q is hydrogen or Calkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

The invention provides compounds of the formula 

2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use

The invention provides compounds of formula (I): wherein The compounds are useful in therapy, in particular as antipsychotic agents.

Sulfonamide derivatives as antipsychotic agents

The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Indole derivatives as 5-HT receptor antagonist

Indoline derivatives useful as 5-HT-2C receptor antagonists

Sulphonamide compounds according to formula (I) or pharmaceutically acceptable salts thereof:

Sulphonamide derivatives and their use in the treatment of CNS disorders

A compound of formula (I) or a salt thereof:

Growing community of inventors

Harlow, United Kingdom

Ian Thomson Forbes